Clinical distribution and drug resistance analysis of AmpC β-lactamase and ESBLs producing Enterobacter cloacae
10.3760/cma.j.issn.1673-4130.2009.01.007
- VernacularTitle:产AmpC酶和ESBLs阴沟肠杆菌的临床分布及耐药性分析
- Author:
Zhenhua TANG
;
Yilang ZHU
- Publication Type:Journal Article
- Keywords:
Enterobacter cloacae;
beta Lactamases;
Drug resistance，bacterial
- From:
International Journal of Laboratory Medicine
2009;30(1):16-19
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the status of AmpC β-lactamase and extended spectrum β-lactamases (ESBLs) production and drug-resistance characteristic of Enterobacter cloacae.Methods Enterobacter cloacae was isolated and cultured from variety of specimens from April 2005 to July 2007. VITEK32 automatic microbial analytical system was applied to performing identification of bacteria and susceptibility test. ESBLs were confirmed by NCCLS double disc assay, and three-dimensional test was used to detect AmpC.Results A total of 63 strains of Enterobacter cloacae were isolated, including 13(20.6%) single AmpC producing strains, 24(31.8%) single ESBLs producing strains, 6(9.5%) both AmpC and ESBLs producing strains, and 20(38.1%) neither AmpC nor ESBLs producing strains. The resistance of lactamases producing strains was significantly higher than that of lactamases non-producing ones. Especially in both AmpC and ESBLs producing strains, the drug resistance was serous.Conclusion The prevalence of AmpC β-lactamases and/or ESBLs producing strains is a higher level in Fuyang area. The drug resistance of AmpC β-lactamases producing Enterobacter cloacae isn′t identical to that of ESBLs producing one. Different categories of antibacterials should be chosen according to the different types of producing lactamases.
